MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, received a suspension order for a drug license of a store situated in Maharashtra.

Regulatory Action Details

The suspension order was issued by the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Maharashtra, specifically by Mr. R.V. Pongale. The action targets a store located in Sasanenagar, Pune, Maharashtra, with the suspension effective for fifteen days.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of Rs 6.27 lacs due to the fifteen-day suspension of the drug license for the affected store.

Regulatory Compliance

The disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The violation relates to Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Corporate Communication

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on the websites of BSE Limited and National Stock Exchange of India Ltd. The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on February 04, 2026.

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, has received a drug license suspension order from Maharashtra's drug regulatory authority.

Regulatory Action Details

The suspension order was issued by the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Bhandara, Maharashtra. The action targets a specific store location and carries significant operational implications for the subsidiary.

Legal Framework and Violations

The suspension has been imposed under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. This regulatory framework governs the licensing and operation of pharmaceutical retail establishments across India. The specific nature of the violation or contravention that led to this action falls under these established pharmaceutical regulations.

Financial Impact Assessment

The company has quantified the potential financial implications of this regulatory action. The suspension is expected to result in a potential revenue loss of Rs 7.53 lacs for the affected store during the suspension period.

Regulatory Compliance and Disclosure

MedPlus Health Services has made this disclosure pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The disclosure falls under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has confirmed that complete details of this matter will be available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited. Company Secretary & Compliance Officer Manoj Kumar Srivastava signed the regulatory filing on January 31, 2026.